Background and Objective: Neurologic literatrure about therapeutic effect of subcutaneous corticosteroids in patients with migrainous chronic daily headache is scare. Aim of this research is assessment of therapeutic effects of this management in the patients.
Methods: Consecutive patients with migrainous chronic daily headache in our headache clinic enrolled a prospective before and after therapeutic study during 2010-2013. Fourty mg Metylprednisolone was divided in four subcutaneous injection doses. Two injections were done in right and left suboccipital area exactly at retromastoid cervicocranial junction and two injections were performed in lower medial frontal area exactly at medial right and left eye brow limit. A headache daily was filled out by the patient before and one month after intervention. The severity of pain was classified based on the Pain Intensity Instrument, using a 0-to-10 point numeric rating scale. Paired t test and Chi-square served for statistical analysis.
Results: 504 patients (378 females, 126 males) with migrainous chronic daily headache underwent the study. Dramatic, significant, moderate and mild or no improvement constituted 28.6%, 33.3%, 23.8%, and 14.3% of the post treatment courses respectively. Therapeutic effect of intervention on mean pain scores was significant; t=7.38, df=20, p=.000. Two cases developed subcutaneous fat atrophy in frontal injection site and 3 cases experienced syncope during injection.
Conclusion: Subcutaneous
Migraine headaches are the third most prevalent illness in the world, and ranked as the sixth most disabling illness. Statistics show that only about fifty percent of people who suffer from chronic headaches know that they’re suffering from a migraine. 76% of people who suffer from migraines worry that they will suffer for the rest of their lives, and 37% of sufferers worried about their migraines between attacks. Studies found that approximately 12% of Americans suffer from migraines, and 40% of Americans could benefit from preventative therapies. Even though studies show that at least 40% of sufferers could benefit from preventative therapies, only one in five sufferers are currently using preventative therapies. Studies also show that over 25% of people who suffer from migraine attacks miss at least one working day over the past three months, and nine out of ten sufferers say that they cannot “function normally” during those days. At least 98 percent of migraine attack sufferers take medications for temporary headache relief, whether it be over the counter or prescription. Only 12% of sufferers take preventative medications as opposed to the 98% of sufferers taking medications for relief. Severe migraines are ranked in the highest of seven disability classes, along with psychosis, dementia, and quadriplegia, published by the World Health Organization. People who participated in a survey who admitted to a
Migraines contrary to old beliefs are not just bad headaches! Migraines are actually a neurological disease that affects 38 million people worldwide, according to the Migraine Research Foundation, 1 in 4 U.S households have at least one person who suffers from debilitating migraines living there. Although there is no cure for migraines, the vast majority of these victims use Excedrin Migraine or Advil Migraine to try to dull the sharp, throbbing pains they experience. These over the counter pain relievers may be very similar but they also have many differences.
The main ar-gument of the article is that neuropathic pain is challenging to manage and is a signifi-cant burden on society. The authors highlight how intrathecal drug delivery can be an alternate intervention for neuropathic pain when other methods of treatment fail to re-lieve symptoms. The topics covered in the article are the various medications used to manage neuropathic pain such as opioids, alpha-2 adrenergic agonists, calcium channel blockers, gamma-aminobutyric acid agonists, local anaesthetics, and corticosteroids. Ev-idence shows that intrathecal opioids may provide long term benefits for neuropathic pain, with other medications such as baclofen, ziconotide, bupivacaine, clonidine also showing moderate evidence of effective management of neuropathic
The etiology of chronic pain is complex and may be due to a number of different factors. Current therapeutics often fail to produce adequate analgesia for moderate-to-severe pain
Migraines affect nearly 28 million people or 12% of the population in the United States. Migraines are typified by moderate to severe head pain. The head pain is often accompanied by one or more of the following; nausea, photophobia, phonophobia or vomiting. Migraines are considered a chronic neurological disorder. The incidence of migraine related nausea (MRN) is very high among migraneurs. Roughly 90% of patients experience MRN at one time or another. Roughly 50% of patients report experiencing MRN with high frequency (greater than half the time). MRN can hinder the efficacy of currently available migraine drugs in a number of ways. Many patients who experience MRN will delay or avoid taking oral or nasal migraine medication as it can further irritate their stomach. The GI upset associated with migraines can also affect absorption and thus limit systemic exposure to the drug. Researchers have been working diligently to find a solution to this problem.
There are many people worldwide who suffer from migraine disorders. Any episodic migraine if not treated properly can lead to chronic Migraine, which is more than 15 migraine headaches per month. To prevent this condition and help patients to manage their migraine headaches, neurologists suggest cognitive behavioral therapy along with pharmaceutical treatments. To assess the efficacy of non-drug behavioral intervention in treatment and prevention of CM, a qualitative study can be established on a focused group of people. Those who have established Migraines diagnosis, who have shown limited benefits from medication or have intolerant side effects to pharmaceutical therapy will be in a semi structured guided interview for this study. The chosen
Other nonpharmacological options that may be beneficial in the prevention of migraine headaches include: biofeedback, other forms of relaxation training, cognitive-behavioral therapies, acupuncture, and transcutaneous electrical
Pain is often an unpleasant part of being human. The experience is different for every individual person and, the result of the pain does not always depend on the stimulus but can be effected by the contest of any given situation. Neuropathic and nociceptive pain serve no observable purpose and can often be an immense burden on the lives of the people that suffer from chronic and neuropathic pain. Their physical, mental and emotional health can be seriously impacted as well as their social life, and even their career or occupation can be negatively impacted by it. Analgesic treatments that are currently available are extremely limiting, they suffer from low effectiveness, extreme financial costs and potentially harmful toxicity factors. This
Each year over twenty-six million people nation wide are affected by migraines. Once thought to be a concentration of evil spirits in the brain, common cures consisted of everything from drilling holes in the skull, to inserting garlic cloves into the temples. Today however, scientists realize that this all too common occurrence is actually a neurological disorder, which can result in the disability of its victim for hours or even days. I myself have been a constant sufferer of migraines since the age of twelve. The following is the life of a migraine sufferer: myself.
The severity score resulted in a 60% improvement from 55 to 22. Lastly, the frequency of headaches improved 62%, a decrease from 18 to 7 over the 2-week period (Whittingham, Ellis, Molyneux, 1994).
Is your chronic pain all in your head? In a manner of speaking, it is. Learn how your brain responds to
Now, hundreds of years later, researchers are engaged in the continuing search for proof of the true pathogenesis of migraine and its cure. What has thus far been accepted is the rather vague definition of migraine headache as "a primary episodic headache disorder characterized by various combinations of neurological, gastrointestinal and autonomic changes" (1). Yet for its pervasiveness and deleterious effects, what do we truly understand about migraine headache? How is migraine related to other neurological dysfunction? Is there a cure? if so, how can it be found?
Introduction: Migraine is a chronic disorder of the brain with significant morbidity, as well as personal, familial and socioeconomically impact. It affects about 12 percent of the general population and affects three times more women than men. Migraine disability is related to the severity of attacks together with the number of attacks and number and type of coexisting morbidities. Migraine is a serious and widespread health problem and is considered the sixth highest cause of disability worldwide, while medication overuse headaches follow at eighteenth. By adding these two conditions together, headache becomes the third most common cause of disability worldwide. All migraineurs require acute care treatment, and up to 40 % of episodic migraineurs could benefit from preventive treatment; but few undertake it. All patients with chronic migraine should
I have extensively treated Hugo for Migraine disease since May 9, 2014. He has experienced severe thrashing migraines as of late 2013. When Hugo experiences these throbbing headaches, he may be subjected to dizziness, sensitivity to light, noise, and smells. I can testify from past consultations that he is extremely sensitive to light, and even physical movement. This explains why Hugo has missed a number of classes, due to the severe pain, sensitivity to light, and physical movement. I have conducted a number of neurological exams, along with several treatments and medications that have been impermanently favorable. Migraine is a neurological disease that is incurable, yet it can be successfully prevented and treated. Unfortunately, I have
One basic inquiry regarding headache medicine and different pharmaceuticals is, "The manner by which does it know how to get to where the torment is?" The answer is that it doesn't! When you take headache medicine, it disintegrates in your stomach or the following some portion of the digestive tract, the small digestive system, and your body assimilates it there. At that point it goes into the circulation system and it experiences your whole body. In spite of the fact that it is all around, it just works where there are prostaglandins being made, which incorporates the region where it harms.